Prostate Cancer — Microlearning Activity 1 with Dr Rana R McKay: ESMO Congress 2025 Review
Research To Practice | Oncology Videos
Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00) Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18) Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14)
info_outline
HER2-Positive Gastrointestinal Cancers — Proceedings from a Session Held Adjunct to the 2026 ASCO Gastrointestinal Cancers Symposium
Research To Practice | Oncology Videos
Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics: Introduction (0:00) Biliary Tract Cancers — Dr Ellis (1:56) Gastroesophageal Cancers — Dr Wainberg (24:27) Colorectal Cancer — Prof Van Cutsem (59:13)
info_outline
Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
Research To Practice | Oncology Videos
Featuring perspectives from Dr Angela DeMichele, Dr Komal Jhaveri, Dr Erica Mayer, Dr Hope S Rugo and Dr Seth Wander, including the following topics: Introduction (0:00) 1985 NCI Consensus Conference on Early Breast Cancer: Sir Richard Peto, FRS (2:01) Current Role of Genomic Assays in Treatment Decision-Making for Localized Hormone Receptor (HR)-Positive Breast Cancer — Dr DeMichele (5:13) Case: A premenopausal woman in her mid 40s with an ER-positive, HER2-negative, node-negative infiltrating ductal carcinoma (IDC) after partial mastectomy/radiation therapy who enrolls in the...
info_outline
Metastatic Bladder Cancer — Rapid Case Review Issue 1
Research To Practice | Oncology Videos
Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: Case: A man in his early 60s with metastatic urothelial bladder cancer (mUBC) and medical history of tobacco use receives first-line enfortumab vedotin (EV) and pembrolizumab with excellent response after 3 cycles — Dr Fahey (0:00) Case: A woman in her early 80s with tumor mutational burden-high mUBC receives pembrolizumab with complete response and later discontinues after developing Grade 1 pneumonitis has no further evidence of disease...
info_outline
Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review
Research To Practice | Oncology Videos
Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics: Introduction (0:00) Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24) Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10) Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO...
info_outline
Relapsed/Refractory Multiple Myeloma — ASH 2025 Review
Research To Practice | Oncology Videos
Featuring perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics: Introduction (0:00) Best of ASH Multiple Myeloma (1:56) Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35) Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58) Case: A man in his...
info_outline
HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
Research To Practice | Oncology Videos
Featuring perspectives from Prof Giuseppe Curigliano, Prof Nadia Harbeck, Dr Ian E Krop, Dr Nancy U Lin and Dr Joyce O’Shaughnessy, including the following topics: Introduction (0:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck (1:39) Case: A woman in her mid 50s presents with locally advanced ER-positive, HER2-positive breast cancer — Alan B Astrow, MD (12:52) Case: A woman in her mid 40s with ER-positive, HER2-positive Stage II breast cancer s/p neoadjuvant TCHP with residual disease receives adjuvant T-DM1 but discontinues...
info_outline
Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Research To Practice | Oncology Videos
Featuring perspectives from Dr Nancy L Bartlett, Dr John P Leonard, Dr Matthew Matasar, Dr Loretta J Nastoupil and Prof Pier Luigi Zinzani, including the following topics: Introduction (0:00) Rational Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Matasar (1:34) Case: A man in his late 50s who presents with left testicular swelling and abdominal discomfort is diagnosed with ABC-subtype Stage IV DLBCL — Laurie H Sehn, MD, MPH (11:27) Clinical Utility of CD19-Directed Monoclonal Antibodies for DLBCL...
info_outline
Colorectal Cancer — 5-Minute Journal Club Issue 2 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Research To Practice | Oncology Videos
Featuring an interview with Dr Scott Kopetz, including the following topics: Circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy de-escalation in the treatment of Stage III colon cancer from the ctDNA-negative cohort of the DYNAMIC-III trial (0:00) Prognostic and predictive role of ctDNA in the management of Stage III colon cancer treated with celecoxib: Findings from the CALGB (Alliance)/SWOG 80702 trial (8:01) Phase III ALTAIR study comparing trifluridine/tipiracil to placebo for patients with molecular residual disease after curative resection of colorectal cancer (CRC); a...
info_outline
Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Research To Practice | Oncology Videos
Featuring perspectives from Prof Claire Harrison, Dr Andrew T Kuykendall, Dr Stephen T Oh, Dr Jeanne Palmer and Dr Raajit K Rampal, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Palmer (1:46) Case: A woman in her mid 70s presents with symptomatic JAK2 V61F-mutant primary MF with mild anemia and normal platelet count — John Mascarenhas, MD (16:09) Discussion: Asymptomatic MF; re-reads of pathology reports; “triple-negative” MF; secondary causes — Laura C Michaelis, MD (22:47)...
info_outlineFeaturing perspectives from Dr Yelena Y Janjigian, including the following topics:
- Introduction (0:00)
- Case: A man in his early 60s with a history of Barrett's esophagus presents with HER2-positive metastatic esophageal adenocarcinoma and a PD-L1 combined positive score (CPS) of 3 — Jennifer Yannucci, MD (10:20)
- Case: A man in his early 60s with multiregimen-recurrent HER2-positive gastroesophageal junction (GEJ) adenocarcinoma (claudin 18.2-positive, PD-L1 CPS 0) — Neil Morganstein, MD (14:53)
- Case: A woman in her early 80s with dementia and newly diagnosed mismatch repair-deficient, PD-L1-positive metastatic GEJ adenocarcinoma — Brian P Mulherin, MD (25:55)
- Case: A man in his mid 60s with localized HER2-negative GEJ cancer (PD-L1 CPS 2, claudin 18.2-positive) and residual disease after receiving neoadjuvant chemoradiation therapy and undergoing surgery — Stephen "Fred" Divers, MD (32:18)
- Case: A man in his early 80s with metastatic recurrence of esophageal adenocarcinoma and a PD-L1 total proportion score of 75% 2 years after resection of localized disease — Susmitha Apuri, MD (40:28)
- Case: A man in his mid 70s with claudin 18.2-positive metastatic esophageal adenocarcinoma who develops progressive toxicities with FOLFOX and zolbetuximab — Sean Warsch, MD (52:54)